Literature DB >> 2668307

Metoprolol-controlled release, zero order kinetics.

M J Kendall1.   

Abstract

Metoprolol CR/ZOK (controlled release, zero order kinetics) is a new formulation of an extensively used beta 1-selective, beta-adrenoceptor blocking drug, (beta 1-blocker), designed to provide continuous, even, plasma concentrations in the therapeutic range. It should, therefore, provide an effective well-tolerated treatment for hypertension and angina pectoris and for use in secondary prevention following a myocardial infarct. The purpose of this review is to consider the need for such a formulation, to describe its pharmaceutical development, review its pharmacology and assess its efficacy and tolerability compared with other available agents.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2668307     DOI: 10.1111/j.1365-2710.1989.tb00235.x

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  4 in total

Review 1.  Beta-blockers for Atherosclerosis Prevention: a Missed Opportunity?

Authors:  Michal Vrablik; Alberto Corsini; Eva Tůmová
Journal:  Curr Atheroscler Rep       Date:  2022-02-16       Impact factor: 5.113

Review 2.  Controlled release metoprolol formulations. A review of their pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and ischaemic heart disease.

Authors:  G L Plosker; S P Clissold
Journal:  Drugs       Date:  1992-03       Impact factor: 9.546

3.  Medication adherence during laboratory workup for primary aldosteronism: pilot study.

Authors:  Friederike A Sandbaumhüter; Manuel Haschke; Bruno Vogt; Jürgen M Bohlender
Journal:  Patient Prefer Adherence       Date:  2018-11-19       Impact factor: 2.711

Review 4.  Carboxylic Acid Counterions in FDA-Approved Pharmaceutical Salts.

Authors:  Sonali S Bharate
Journal:  Pharm Res       Date:  2021-07-23       Impact factor: 4.200

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.